<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02510040</url>
  </required_header>
  <id_info>
    <org_study_id>SAS1</org_study_id>
    <secondary_id>2U10EY011751</secondary_id>
    <nct_id>NCT02510040</nct_id>
  </id_info>
  <brief_title>A Prospective Observational Study of Adult Strabismus</brief_title>
  <acronym>SAS1</acronym>
  <official_title>A Prospective Observational Study of Adult Strabismus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Eye Disease Investigator Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe clinical characteristics, treatments, and one-year&#xD;
      outcomes of adults with convergence insufficiency, divergence insufficiency, or small angle&#xD;
      hypertropia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to describe clinical characteristics, treatments, and one-year&#xD;
      outcomes of adults with convergence insufficiency, divergence insufficiency, or small angle&#xD;
      hypertropia. Treatment comparisons within the studied conditions will also be done to help&#xD;
      develop future studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2015</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Symptom Success at 10 Weeks</measure>
    <time_frame>10 weeks after enrollment</time_frame>
    <description>In the convergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as improvement of CI Symptom Survey (CISS) score of at least 9 points and an outcome score of &lt;21 points. In the divergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia &quot;rarely&quot; or &quot;never&quot; in primary position at distance on the diplopia questionnaire. In the small-angle hypertropia group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia &quot;rarely&quot; or &quot;never&quot; both in primary position at distance and in reading position on the diplopia questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Symptom Success at 12 Months</measure>
    <time_frame>12 months after enrollment</time_frame>
    <description>In the convergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as improvement of CI Symptom Survey (CISS) score of at least 9 points and an outcome score of &lt;21 points. In the divergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia &quot;rarely&quot; or &quot;never&quot; in primary position at distance on the diplopia questionnaire. In the small-angle hypertropia group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia &quot;rarely&quot; or &quot;never&quot; both in primary position at distance and in reading position on the diplopia questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Near Point of Convergence</measure>
    <time_frame>12 months after enrollment</time_frame>
    <description>Near point of convergence (convergence insufficiency group only). The data for the Convergence Insufficiency group is not yet available as analysis is ongoing. Results are expected May 2021.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Fusional Vergence</measure>
    <time_frame>12 months after enrollment</time_frame>
    <description>Positive fusional vergence (convergence insufficiency group only). The data for the Convergence Insufficiency group is not yet available as analysis is ongoing. Results are expected May 2021.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Strabismus 20 Questionnaire Score (DI)</measure>
    <time_frame>12 months after enrollment</time_frame>
    <description>Adult Strabismus Quality of Life Questionnaire (AS-20) For AS-20, scores are reported for the following subscales. A total score will not be reported.&#xD;
Self-perception score&#xD;
Interaction score&#xD;
Reading function score&#xD;
General function score Values for each subscale range from 0 to 100. 0 indicates poor quality of life (the patient reported &quot;always&quot; for all questions) and 100 represents good quality or life (patient reported &quot;never&quot; for all questions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Convergence Insufficiency Symptom Survey Score</measure>
    <time_frame>12 months after enrollment</time_frame>
    <description>Mean Convergence Insufficiency Symptom Survey Score (convergence insufficiency group only) For CISS, the range is from 0 (having no symptoms of CI) to 60 (always showing all symptoms of CI).&#xD;
The data for the Convergence Insufficiency group is not yet available as analysis is ongoing. Results are expected May 2021.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Strabismus 20 Questionnaire Score (CI)</measure>
    <time_frame>12 months after enrollment</time_frame>
    <description>Adult Strabismus Quality of Life Questionnaire (AS-20) For AS-20, scores are reported for the following subscales. A total score will not be reported.&#xD;
Self-perception score Interaction score Reading function score General function score Values for each subscale range from 0 to 100. 0 indicates poor quality of life (the patient reported &quot;always&quot; for all questions) and 100 represents good quality or life (patient reported &quot;never&quot; for all questions)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">217</enrollment>
  <condition>Convergence Insufficiency</condition>
  <condition>Divergence Insufficiency</condition>
  <condition>Hypertropia</condition>
  <arm_group>
    <arm_group_label>Convergence insufficiency</arm_group_label>
    <description>Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Divergence insufficiency</arm_group_label>
    <description>Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Small-angle hypertropia</arm_group_label>
    <description>Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prism</intervention_name>
    <description>Ground-in or Fresnel prism</description>
    <arm_group_label>Convergence insufficiency</arm_group_label>
    <arm_group_label>Divergence insufficiency</arm_group_label>
    <arm_group_label>Small-angle hypertropia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Orthoptic Exercises</intervention_name>
    <description>Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy</description>
    <arm_group_label>Convergence insufficiency</arm_group_label>
    <arm_group_label>Divergence insufficiency</arm_group_label>
    <arm_group_label>Small-angle hypertropia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Eye Muscle Surgery</intervention_name>
    <description>Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery</description>
    <arm_group_label>Convergence insufficiency</arm_group_label>
    <arm_group_label>Divergence insufficiency</arm_group_label>
    <arm_group_label>Small-angle hypertropia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Botox Injection</intervention_name>
    <description>Botulinum toxin injection</description>
    <arm_group_label>Convergence insufficiency</arm_group_label>
    <arm_group_label>Divergence insufficiency</arm_group_label>
    <arm_group_label>Small-angle hypertropia</arm_group_label>
    <other_name>Botulinum toxin injection</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Community Sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Eligibility Criteria for Convergence Insufficiency (CI) Group:&#xD;
&#xD;
        The following inclusion criteria must be met for the subject to be enrolled into the study:&#xD;
&#xD;
          -  Adults ≥18 years of age (adult onset of CI not required)&#xD;
&#xD;
          -  No strabismus surgery within the past 10 years&#xD;
&#xD;
          -  CI Symptom Survey score ≥21 points&#xD;
&#xD;
          -  Near exodeviation of ≥4∆ and at least 4∆ larger than at distance by PACT&#xD;
&#xD;
          -  Distance exodeviation ≤15∆ by PACT&#xD;
&#xD;
          -  Vertical deviation ≤2∆ at distance and near by PACT&#xD;
&#xD;
          -  No constant exotropia at distance or near&#xD;
&#xD;
          -  Reduced positive fusional vergence (PFV) at near (&lt;20∆ or fails Sheard's criterion&#xD;
             that the PFV measures less than twice the magnitude of the near phoria)&#xD;
&#xD;
          -  Near point of convergence (NPC) of ≥6 cm break&#xD;
&#xD;
          -  Visual acuity 20/50 or better in both eyes by ETDRS or Snellen&#xD;
&#xD;
          -  No paralytic strabismus (e.g., 3rd, 4th, or 6th cranial nerve palsies, skew deviation,&#xD;
             Duane syndrome)&#xD;
&#xD;
          -  No restrictive strabismus (e.g., blowout fracture, thyroid eye disease, post scleral&#xD;
             buckle, Brown syndrome)&#xD;
&#xD;
          -  No monocular diplopia&#xD;
&#xD;
          -  No paretic strabismus, thyroid eye disease, myasthenia gravis, chronic progressive&#xD;
             external ophthalmoplegia, or eye movement abnormalities associated with known&#xD;
             neurological disease. Patients with Parkinson's disease can be enrolled if non-paretic&#xD;
             deviation.&#xD;
&#xD;
          -  No inferior or superior oblique overaction defined as 2+ or greater&#xD;
&#xD;
          -  Ability to fuse with prism in space (see section 2.4.1)&#xD;
&#xD;
          -  Ability to understand and complete a survey&#xD;
&#xD;
          -  Investigator is initiating treatment with prism, orthoptic exercises, botulinum toxin&#xD;
             injection or surgery&#xD;
&#xD;
          -  If initiating treatment with botulinum toxin or surgery, planned injection or surgery&#xD;
             to be within 60 days of enrollment&#xD;
&#xD;
          -  Single treatment modality is planned (e.g., no combined prism and orthoptic exercises)&#xD;
&#xD;
          -  Treatment to be initiated has not been used within the past one year&#xD;
&#xD;
        Eligibility Criteria for Divergence Insufficiency (DI) Group:&#xD;
&#xD;
        The following inclusion criteria must be met for the subject to be enrolled into the study:&#xD;
&#xD;
          -  Adults ≥18 years of age&#xD;
&#xD;
          -  Adult-onset DI (at ≥18 years of age)&#xD;
&#xD;
          -  No prior strabismus surgery&#xD;
&#xD;
          -  Symptoms of diplopia at distance with a frequency of sometimes or worse in primary&#xD;
             position (in current glasses if wearing glasses)&#xD;
&#xD;
          -  Distance esodeviation of 2∆ to 30∆ and at least 50% larger than at near by PACT&#xD;
&#xD;
          -  No more than 5∆ difference between right and left gaze by PACT&#xD;
&#xD;
          -  No more than 10∆ difference between the primary position at distance and either upgaze&#xD;
             or downgaze ≤10∆ by PACT&#xD;
&#xD;
          -  Any coexisting vertical deviation must be less than distance esodeviation and ≤10∆ by&#xD;
             PACT&#xD;
&#xD;
          -  Visual acuity 20/50 or better in both eyes by ETDRS or Snellen&#xD;
&#xD;
          -  No paralytic strabismus (e.g., 3rd, 4th, or 6th cranial nerve palsies, skew deviation,&#xD;
             Duane syndrome)&#xD;
&#xD;
          -  No restrictive strabismus (e.g., blowout fracture, thyroid eye disease, post scleral&#xD;
             buckle, Brown syndrome)&#xD;
&#xD;
          -  No monocular diplopia&#xD;
&#xD;
          -  No paretic strabismus, thyroid eye disease, myasthenia gravis, chronic progressive&#xD;
             external ophthalmoplegia, or eye movement abnormalities associated with known&#xD;
             neurological disease. Patients with Parkinson's disease can be enrolled if non-paretic&#xD;
             deviation&#xD;
&#xD;
          -  No inferior or superior oblique overaction defined as 2+ or greater&#xD;
&#xD;
          -  Ability to fuse with prism in space (see section 2.4.2)&#xD;
&#xD;
          -  Ability to understand and complete a survey&#xD;
&#xD;
          -  Investigator is initiating treatment with prism, orthoptic exercises, botulinum toxin&#xD;
             injection or surgery&#xD;
&#xD;
          -  If initiating treatment with botulinum toxin or surgery, planned injection or surgery&#xD;
             to be within 60 days of enrollment&#xD;
&#xD;
          -  Single treatment modality planned (e.g., no combined prism and orthoptic exercises)&#xD;
&#xD;
          -  Treatment to be initiated has not been used within the past one year&#xD;
&#xD;
        Eligibility Criteria for Small-angle Hypertropia (HT) Group:&#xD;
&#xD;
        The following inclusion criteria must be met for the subject to be enrolled into the study:&#xD;
&#xD;
          -  Adults ≥18 years of age&#xD;
&#xD;
          -  Adult-onset HT (at ≥18 years of age)&#xD;
&#xD;
          -  No prior strabismus surgery&#xD;
&#xD;
          -  Symptoms of diplopia at distance or near with a frequency of sometimes or worse in&#xD;
             primary or reading position (in current glasses if wearing glasses)&#xD;
&#xD;
          -  Vertical deviation ≥1∆ to ≤10∆ at distance and near by PACT&#xD;
&#xD;
          -  No more than 4∆ difference from the primary in any gaze position by PACT&#xD;
&#xD;
          -  Any coexisting esodeviation must be less than the vertical deviation&#xD;
&#xD;
          -  Any coexisting exodeviation ≤10∆ by PACT&#xD;
&#xD;
          -  No convergence insufficiency as defined in section 2.2.1&#xD;
&#xD;
          -  Visual acuity 20/50 or better in both eyes by ETDRS or Snellen&#xD;
&#xD;
          -  No paralytic strabismus (e.g., 3rd, 4th, or 6th cranial nerve palsies, skew deviation,&#xD;
             Duane syndrome)&#xD;
&#xD;
          -  No restrictive strabismus (e.g., blowout fracture, thyroid eye disease, post scleral&#xD;
             buckle, Brown syndrome)&#xD;
&#xD;
          -  No monocular diplopia&#xD;
&#xD;
          -  No paretic strabismus, thyroid eye disease, myasthenia gravis, chronic progressive&#xD;
             external ophthalmoplegia, or eye movement abnormalities associated with known&#xD;
             neurological disease. Patients with Parkinson's disease can be enrolled if non-paretic&#xD;
             deviation.&#xD;
&#xD;
          -  No inferior or superior oblique overaction defined as 2+ or greater&#xD;
&#xD;
          -  Ability to fuse with prism in space (see section 2.4.3)&#xD;
&#xD;
          -  Ability to understand and complete a survey&#xD;
&#xD;
          -  Investigator is initiating treatment with prism, orthoptic exercises, botulinum toxin&#xD;
             injection or surgery&#xD;
&#xD;
          -  If initiating treatment with botulinum toxin or surgery, planned injection or surgery&#xD;
             to be within 60 days of enrollment&#xD;
&#xD;
          -  Single treatment modality planned (e.g., no combined prism and orthoptic exercises)&#xD;
&#xD;
          -  Treatment to be initiated has not been used within the past one year&#xD;
&#xD;
        Exclusion Criteria for Convergence Insufficiency (CI) Group:&#xD;
&#xD;
        The following criteria exclude a subject from enrollment into the study:&#xD;
&#xD;
          -  Strabismus surgery within the past 10 years&#xD;
&#xD;
          -  CI Symptom Survey score ≥21 points&#xD;
&#xD;
          -  Near exodeviation of ≤4∆ and at least 4∆ larger than at distance by PACT&#xD;
&#xD;
          -  Distance exodeviation ≥15∆ by PACT&#xD;
&#xD;
          -  Vertical deviation ≥2∆ at distance and near by PACT&#xD;
&#xD;
          -  Constant exotropia at distance or near&#xD;
&#xD;
          -  Near point of convergence (NPC) of ≤6 cm break&#xD;
&#xD;
          -  Visual acuity worse than 20/50 either eye by ETDRS or Snellen&#xD;
&#xD;
          -  Paralytic strabismus (e.g., 3rd, 4th, or 6th cranial nerve palsies, skew deviation,&#xD;
             Duane syndrome)&#xD;
&#xD;
          -  Restrictive strabismus (e.g., blowout fracture, thyroid eye disease, post scleral&#xD;
             buckle, Brown syndrome)&#xD;
&#xD;
          -  Monocular diplopia&#xD;
&#xD;
          -  Paretic strabismus, thyroid eye disease, myasthenia gravis, chronic progressive&#xD;
             external ophthalmoplegia, or eye movement abnormalities associated with known&#xD;
             neurological disease. Patients with Parkinson's disease can be enrolled if non-paretic&#xD;
             deviation.&#xD;
&#xD;
          -  Inferior or superior oblique overaction defined as 2+ or greater&#xD;
&#xD;
          -  Inability to fuse with prism in space (see section 2.4.1)&#xD;
&#xD;
          -  Inability to understand and complete a survey&#xD;
&#xD;
          -  Treatment to be initiated has already been used within the past one year&#xD;
&#xD;
        Exclusion Criteria for Divergence Insufficiency (DI) Group:&#xD;
&#xD;
        The following criteria exclude a subject from enrollment into the study:&#xD;
&#xD;
          -  No adult-onset DI (at ≥18 years of age)&#xD;
&#xD;
          -  Prior strabismus surgery&#xD;
&#xD;
          -  Distance esodeviation outside the range of 2∆ to 30∆ and less than 50% larger than at&#xD;
             near by PACT&#xD;
&#xD;
          -  More than 5∆ difference between right and left gaze by PACT&#xD;
&#xD;
          -  More than 10∆ difference between the primary position at distance&#xD;
&#xD;
          -  Any coexisting vertical deviation more than distance esodeviation and ≥10∆ by PACT&#xD;
&#xD;
          -  Visual acuity worse than 20/50 in either eye by ETDRS or Snellen&#xD;
&#xD;
          -  Paralytic strabismus (e.g., 3rd, 4th, or 6th cranial nerve palsies, skew deviation,&#xD;
             Duane syndrome)&#xD;
&#xD;
          -  Restrictive strabismus (e.g., blowout fracture, thyroid eye disease, post scleral&#xD;
             buckle, Brown syndrome)&#xD;
&#xD;
          -  Monocular diplopia&#xD;
&#xD;
          -  Paretic strabismus, thyroid eye disease, myasthenia gravis, chronic progressive&#xD;
             external ophthalmoplegia, or eye movement abnormalities associated with known&#xD;
             neurological disease.&#xD;
&#xD;
          -  Inferior or superior oblique overaction defined as 2+ or greater&#xD;
&#xD;
          -  Inability to fuse with prism in space (see section 2.4.2)&#xD;
&#xD;
          -  Inability to understand and complete a survey&#xD;
&#xD;
          -  Treatment to be initiated has already been used within the past one year&#xD;
&#xD;
        Exclusion Criteria for Small-angle Hypertropia (HT) Group:&#xD;
&#xD;
        The following criteria exclude a subject from enrollment into the study:&#xD;
&#xD;
          -  No adult-onset HT (at ≥18 years of age)&#xD;
&#xD;
          -  Prior strabismus surgery&#xD;
&#xD;
          -  Vertical deviation ≤1∆ or ≥10∆ at distance and near by PACT&#xD;
&#xD;
          -  More than 4∆ difference from the primary in any gaze position by PACT&#xD;
&#xD;
          -  Coexisting esodeviation must not be less than the vertical deviation&#xD;
&#xD;
          -  Coexisting exodeviation ≥10∆ by PACT&#xD;
&#xD;
          -  Convergence insufficiency as defined in section 2.2.1&#xD;
&#xD;
          -  Visual acuity worse than 20/50 in either eye by ETDRS or Snellen&#xD;
&#xD;
          -  Paralytic strabismus (e.g., 3rd, 4th, or 6th cranial nerve palsies, skew deviation,&#xD;
             Duane syndrome)&#xD;
&#xD;
          -  Restrictive strabismus (e.g., blowout fracture, thyroid eye disease, post scleral&#xD;
             buckle, Brown syndrome)&#xD;
&#xD;
          -  Monocular diplopia&#xD;
&#xD;
          -  Paretic strabismus, thyroid eye disease, myasthenia gravis, chronic progressive&#xD;
             external ophthalmoplegia, or eye movement abnormalities associated with known&#xD;
             neurological disease.&#xD;
&#xD;
          -  Inferior or superior oblique overaction defined as 2+ or greater&#xD;
&#xD;
          -  Inability to fuse with prism in space (see section 2.4.3)&#xD;
&#xD;
          -  Inability to understand and complete a survey&#xD;
&#xD;
          -  Treatment to be initiated has already been used within the past one year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Earl R Crouch, III, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Virginia Pediatric Eye Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Earl R. Crouch, III</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502-3942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pedig.jaeb.org</url>
    <description>PEDIG Public Website</description>
  </link>
  <results_reference>
    <citation>Crouch ER, Dean TW, Kraker RT, Miller AM, Kraus CL, Gunton KB, Repka MX, Marsh JD, Del Monte MA, Luke PA, Peragallo JH, Lee KA, Wheeler MB, Daley TJ, Wallace DK, Cotter SA, Holmes JM; Pediatric Eye Disease Investigator Group. A prospective study of treatments for adult-onset divergence insufficiency-type esotropia. J AAPOS. 2021 Aug;25(4):203.e1-203.e11. doi: 10.1016/j.jaapos.2021.02.014. Epub 2021 Jul 13.</citation>
    <PMID>34271207</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2015</study_first_posted>
  <results_first_submitted>November 16, 2020</results_first_submitted>
  <results_first_submitted_qc>March 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2021</results_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Convergence Insufficiency</keyword>
  <keyword>Divergence Insufficiency</keyword>
  <keyword>Small-angle Hypertropia</keyword>
  <keyword>Strabismus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Strabismus</mesh_term>
    <mesh_term>Ocular Motility Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the Pediatric Eye Disease Investigator Group (PEDIG) public website after the completion of each protocol and publication of the primary manuscript.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>After completion of the protocol and publication of the primary manuscript, the data will be made available for the duration of the grant and any future grants.</ipd_time_frame>
    <ipd_access_criteria>public</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02510040/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02510040/SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 10, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02510040/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Convergence Insufficiency</title>
          <description>Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
        </group>
        <group group_id="P2">
          <title>Divergence Insufficiency</title>
          <description>Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
        </group>
        <group group_id="P3">
          <title>Small-angle Hypertropia</title>
          <description>Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Deemed no longer eligible</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Convergence Insufficiency</title>
          <description>Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
        </group>
        <group group_id="B2">
          <title>Divergence Insufficiency</title>
          <description>Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
        </group>
        <group group_id="B3">
          <title>Small-angle Hypertropia</title>
          <description>Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="195"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" spread="18.6"/>
                    <measurement group_id="B2" value="67.4" spread="13.7"/>
                    <measurement group_id="B3" value="68.6" spread="13.0"/>
                    <measurement group_id="B4" value="59.5" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" lower_limit="25.6" upper_limit="57.2"/>
                    <measurement group_id="B2" value="71.2" lower_limit="60.8" upper_limit="75.7"/>
                    <measurement group_id="B3" value="71.5" lower_limit="65.7" upper_limit="76.6"/>
                    <measurement group_id="B4" value="65.3" lower_limit="44.2" upper_limit="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Symptom Success at 10 Weeks</title>
        <description>In the convergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as improvement of CI Symptom Survey (CISS) score of at least 9 points and an outcome score of &lt;21 points. In the divergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia &quot;rarely&quot; or &quot;never&quot; in primary position at distance on the diplopia questionnaire. In the small-angle hypertropia group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia &quot;rarely&quot; or &quot;never&quot; both in primary position at distance and in reading position on the diplopia questionnaire.</description>
        <time_frame>10 weeks after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Convergence Insufficiency</title>
            <description>Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
          </group>
          <group group_id="O2">
            <title>Divergence Insufficiency</title>
            <description>Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
          </group>
          <group group_id="O3">
            <title>Small-angle Hypertropia</title>
            <description>Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptom Success at 10 Weeks</title>
          <description>In the convergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as improvement of CI Symptom Survey (CISS) score of at least 9 points and an outcome score of &lt;21 points. In the divergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia &quot;rarely&quot; or &quot;never&quot; in primary position at distance on the diplopia questionnaire. In the small-angle hypertropia group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia &quot;rarely&quot; or &quot;never&quot; both in primary position at distance and in reading position on the diplopia questionnaire.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Symptom Success at 12 Months</title>
        <description>In the convergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as improvement of CI Symptom Survey (CISS) score of at least 9 points and an outcome score of &lt;21 points. In the divergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia &quot;rarely&quot; or &quot;never&quot; in primary position at distance on the diplopia questionnaire. In the small-angle hypertropia group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia &quot;rarely&quot; or &quot;never&quot; both in primary position at distance and in reading position on the diplopia questionnaire.</description>
        <time_frame>12 months after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Convergence Insufficiency</title>
            <description>Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
          </group>
          <group group_id="O2">
            <title>Divergence Insufficiency</title>
            <description>Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
          </group>
          <group group_id="O3">
            <title>Small-angle Hypertropia</title>
            <description>Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptom Success at 12 Months</title>
          <description>In the convergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as improvement of CI Symptom Survey (CISS) score of at least 9 points and an outcome score of &lt;21 points. In the divergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia &quot;rarely&quot; or &quot;never&quot; in primary position at distance on the diplopia questionnaire. In the small-angle hypertropia group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia &quot;rarely&quot; or &quot;never&quot; both in primary position at distance and in reading position on the diplopia questionnaire.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Near Point of Convergence</title>
        <description>Near point of convergence (convergence insufficiency group only). The data for the Convergence Insufficiency group is not yet available as analysis is ongoing. Results are expected May 2021.</description>
        <time_frame>12 months after enrollment</time_frame>
        <posting_date>10/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Fusional Vergence</title>
        <description>Positive fusional vergence (convergence insufficiency group only). The data for the Convergence Insufficiency group is not yet available as analysis is ongoing. Results are expected May 2021.</description>
        <time_frame>12 months after enrollment</time_frame>
        <posting_date>10/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adult Strabismus 20 Questionnaire Score (DI)</title>
        <description>Adult Strabismus Quality of Life Questionnaire (AS-20) For AS-20, scores are reported for the following subscales. A total score will not be reported.&#xD;
Self-perception score&#xD;
Interaction score&#xD;
Reading function score&#xD;
General function score Values for each subscale range from 0 to 100. 0 indicates poor quality of life (the patient reported &quot;always&quot; for all questions) and 100 represents good quality or life (patient reported &quot;never&quot; for all questions)</description>
        <time_frame>12 months after enrollment</time_frame>
        <population>This information was only collected and analyzed for the DI and CI arms. The HT arm cannot be reported since it was not collected. The CI arm data is currently being analyzed, and will be added to the record when analysis is complete, results are expected May 2021.</population>
        <group_list>
          <group group_id="O1">
            <title>Divergence Insufficiency</title>
            <description>Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
          </group>
        </group_list>
        <measure>
          <title>Adult Strabismus 20 Questionnaire Score (DI)</title>
          <description>Adult Strabismus Quality of Life Questionnaire (AS-20) For AS-20, scores are reported for the following subscales. A total score will not be reported.&#xD;
Self-perception score&#xD;
Interaction score&#xD;
Reading function score&#xD;
General function score Values for each subscale range from 0 to 100. 0 indicates poor quality of life (the patient reported &quot;always&quot; for all questions) and 100 represents good quality or life (patient reported &quot;never&quot; for all questions)</description>
          <population>This information was only collected and analyzed for the DI and CI arms. The HT arm cannot be reported since it was not collected. The CI arm data is currently being analyzed, and will be added to the record when analysis is complete, results are expected May 2021.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Function Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reading Function Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self Perception Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interaction Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Convergence Insufficiency Symptom Survey Score</title>
        <description>Mean Convergence Insufficiency Symptom Survey Score (convergence insufficiency group only) For CISS, the range is from 0 (having no symptoms of CI) to 60 (always showing all symptoms of CI).&#xD;
The data for the Convergence Insufficiency group is not yet available as analysis is ongoing. Results are expected May 2021.</description>
        <time_frame>12 months after enrollment</time_frame>
        <posting_date>10/2021</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adult Strabismus 20 Questionnaire Score (CI)</title>
        <description>Adult Strabismus Quality of Life Questionnaire (AS-20) For AS-20, scores are reported for the following subscales. A total score will not be reported.&#xD;
Self-perception score Interaction score Reading function score General function score Values for each subscale range from 0 to 100. 0 indicates poor quality of life (the patient reported &quot;always&quot; for all questions) and 100 represents good quality or life (patient reported &quot;never&quot; for all questions)</description>
        <time_frame>12 months after enrollment</time_frame>
        <posting_date>10/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was not collected since treatment was prescribed per usual standard of care.</time_frame>
      <desc>Per the study protocol (sections 4.4.1 and 4.5)&#xD;
Risks of Examination Procedures The procedures in this study are part of daily eye care practice in the United States and pose no known risks.&#xD;
Reporting of Adverse Events No treatments are being prescribed that are not part of usual care. Investigators will abide by local IRB reporting requirements.</desc>
      <group_list>
        <group group_id="E1">
          <title>Convergence Insufficiency</title>
          <description>Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
        </group>
        <group group_id="E2">
          <title>Divergence Insufficiency</title>
          <description>Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
        </group>
        <group group_id="E3">
          <title>Small-angle Hypertropia</title>
          <description>Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.&#xD;
Prism: Ground-in or Fresnel prism&#xD;
Orthoptic Exercises: Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy&#xD;
Eye Muscle Surgery: • Bilateral medial rectus muscle resection surgery&#xD;
Single medial rectus muscle resection surgery&#xD;
Recess lateral rectus muscle resection medial rectus muscle surgery&#xD;
Bilateral lateral rectus muscle recession surgery&#xD;
Single lateral rectus muscle recession surgery&#xD;
Bilateral lateral rectus muscle resection surgery&#xD;
Single lateral rectus muscle resection surgery&#xD;
Recess medial rectus muscle resection lateral rectus muscle surgery&#xD;
Bilateral medial rectus muscle recession surgery&#xD;
Single medial rectus muscle recession surgery&#xD;
Vertical rectus muscle recession surgery&#xD;
Vertical rectus muscle mini-tenotomy (snip) surgery&#xD;
Botox Injection: Botulinum toxin injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Raymond Kraker, PEDIG Coordinating Center Director</name_or_title>
      <organization>Jaeb Center for Health Research</organization>
      <phone>813-975-8690</phone>
      <email>rkraker@jaeb.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

